GLOBEALERT
Health● Low1h ago · Nov 4, 2026, 12:27 AM

Madrigal anticipates late 2027 MAESTRO-NASH OUTCOMES readout while planning 2,000+ patient MAESTRO-CSPH study

GlobeAlert Desk · curated from Seeking Alpha Tech · global

Madrigal Pharmaceuticals expects late 2027 results from its MAESTRO-NASH OUTCOMES study and is planning a large MAESTRO-CSPH study with over 2,000 patients. This provides an update on the company's clinical development pipeline.

GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.

GlobeAlert context

What the desk knows about this story

Threat level
0 Low

Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.

Sources
1 publisher

Single-source so far. Treat details as unconfirmed until more publishers report.

Category
Health

Not flagged as developing.

More in Health